Sustained virological and biochemical responses to lamivudine and adefovir dipivoxil combination in a chronic hepatitis B infection despite mutations conferring resistance to both drugs

[1]  Angeline Bartholomeusz,et al.  Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management , 2007, Hepatology.

[2]  George Kitis,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. , 2006, Gastroenterology.

[3]  J. Villeneuve,et al.  Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. , 2006, Gastroenterology.

[4]  J. Villeneuve,et al.  Detection of rtN236T and rtA181V/T Mutations Associated with Resistance to Adefovir Dipivoxil in Samples from Patients with Chronic Hepatitis B Virus Infection by the INNO-LiPA HBV DR Line Probe Assay (Version 2) , 2006, Journal of Clinical Microbiology.

[5]  C. Yurdaydın,et al.  484 A novel mutation pattern developed during lamivudine treatment shows cross-resistance to adefovir dipivoxil treatment , 2006 .

[6]  A. Lok,et al.  Sensitive Line Probe Assay That Simultaneously Detects Mutations Conveying Resistance to Lamivudine and Adefovir , 2006, Journal of Clinical Microbiology.

[7]  J. Marrero,et al.  Virologic response and resistance to adefovir in patients with chronic hepatitis B. , 2006, Journal of hepatology.

[8]  T. Poynard,et al.  Successful rescue therapy with tenofovir in a patient with hepatic decompensation and adefovir resistant HBV mutant , 2006, Comparative Hepatology.

[9]  J. Marrero,et al.  Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. , 2005, Journal of hepatology.

[10]  Graeme Currie,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. , 2005, The New England journal of medicine.

[11]  J. Villeneuve,et al.  Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir , 2005, Hepatology.

[12]  S. Locarnini.  Molecular virology and the development of resistant mutants: implications for therapy. , 2005, Seminars in liver disease.

[13]  P. Cane,et al.  Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR. , 2004, Journal of hepatology.

[14]  C. Gibbs,et al.  Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. , 2003, Journal of hepatology.

[15]  Angeline Bartholomeusz,et al.  Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. , 2003, Gastroenterology.

[16]  M. Wulfsohn,et al.  Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B , 2003, Hepatology.

[17]  Ching-Lung Lai,et al.  Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  Fabien Zoulim,et al.  Monitoring Drug Resistance in Chronic Hepatitis B Virus (HBV)-Infected Patients during Lamivudine Therapy: Evaluation of Performance of INNO-LiPA HBV DR Assay , 2002, Journal of Clinical Microbiology.

[19]  C Summers,et al.  Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). , 1989, Nucleic acids research.